Executives at gene therapy startup Lexeo Therapeutics will likely make the 25-minute trek from their headquarters to Nasdaq’s trading floor later this week in the biotech’s bid for a $113 million initial public offering.
With just $35 million on hand at the end of September, the cardiac and Alzheimer’s biotech will look to the unforgiving public markets as the relatively non-existent IPO window closes ahead of the holidays. On Monday, the company submitted its Nasdaq debut pitch for 9 million shares as “LXEO,” at $13 to $15 apiece.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.